WO2008010620A1 - Compositions comprenant les extraits de matières premières pour améliorer la fonction hépatique - Google Patents

Compositions comprenant les extraits de matières premières pour améliorer la fonction hépatique Download PDF

Info

Publication number
WO2008010620A1
WO2008010620A1 PCT/KR2006/003817 KR2006003817W WO2008010620A1 WO 2008010620 A1 WO2008010620 A1 WO 2008010620A1 KR 2006003817 W KR2006003817 W KR 2006003817W WO 2008010620 A1 WO2008010620 A1 WO 2008010620A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
vitamin
liver
weight
Prior art date
Application number
PCT/KR2006/003817
Other languages
English (en)
Inventor
Jong Moon Jung
Eu Gene Lee
Seung Sook Lee
Ji Hoon Kim
Kyung Bum Kim
Original Assignee
Ben's Lab Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben's Lab Co., Ltd. filed Critical Ben's Lab Co., Ltd.
Publication of WO2008010620A1 publication Critical patent/WO2008010620A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Definitions

  • the present invention relates to a composition for improving liver function and, more particularly, to a composition including an extract of aloe vera, an extract of green tea leaves, an extract of wormwood, an extract of guava leaves, an extract of asparagus, vitamin C, and vitamin B complex.
  • the liver is an organ present in the human body. It functions for storage and circulation of blood, regulation of blood quantity, and detoxification, and is closely related to spirit activity. Since the human body is always exposed to harmful pollutants and toxic substances, the liver is continuously burdened with the process of detoxifying. Additionally, an injury of the human liver caused by a mental stress is a serious problem. A mental relaxation may restore an injured liver, but a busy present- day life does not allow much room for mental relaxation. Furthermore, overdrinking and smoking increase a liver injury, which may often result in a decline in a detoxifying function, a malfunction of a human immunity system, and an outbreak of many diseases.
  • Carbon tetrachloride, D-galactosamine, etc. are known as substances for inducing liver toxicity.
  • Carbon tetrachloride which is a kind of aliphatic halogen hydrocarbon, is a xenobiotic chemical to injure a biological membrane and to invite a toxic operation of the liver and the kidney (Bruckner, J. V., Fund. Appl. Toxicology, 6, ppl6-34; Butler, T. C, /. Pharmacol. Exp. Ther., 134, pp311-319).
  • SLM silymarin
  • BDD biphenyl dimethyl dicarboxylate
  • Inventors of the present invention desired to observe the efficacy of liver function improvements of herb composite medicine which is expected to be clinically effective in prevention or remedy against liver toxicity, and thus desired to evaluate a possibility of an effective remedy for liver toxicity.
  • Aloe vera (Aloe barbadensis Miller) is used in the form of a gel with an aloe peel stripped off.
  • Gel-form aloe vera contains a lot of active ingredients such as polysaccharids which has a high moisturizing capacity, an immunity reinforcing effect, and a curative property, and glycoprotein which decreases blood sugar (Ahn, D. G., the Korean pictorial book of medical herbs, pp280, Kyohak Publishing Company, 2000; Kim, C. M., the colored pictorial book of the herb remedy, pp306, Academy Book Company, 2001).
  • Green tea leaves are leaves of a tea tree (camellia sinensis), also named tea plant.
  • Green tea which is a tea made of non-fermented leaves, is on the increase of consumption according to a recently rising interest in health and is validated with providing a wide variety of health benefits by scientific evidence.
  • catechin Polyphenol of green tea is known as catechin.
  • the followings have been reported as the staple catechins of green tea: epicatechin(EC), epicatechin-3-gallate, epigal- locatechin (EGC), epigallocatechin-3-gallate (EGCG) (Zhao Wenhua, Chen Junshi. /. Clin. Nutr. 10(2), ppl38 ⁇ 142, 2001).
  • Wormwood (A. princeps var. orientalis (PAMPAN.) HARA) is a perennial herb and its leaves contain oil in which cineole is included 25 to 30% by weight. Besides, contained in wormwood are terpinen-4-ol, ⁇ -carophyllene, linalool, artemisia alcohol, camphor, borneol, etc. The leaves contain tetracosanol, ⁇ -sitosterol, 1-chebulachitol, and 1-inositol. The root and the stem contain artemose being similar with inulin.
  • the root also contains a variety of polyin compounds such as heptadec-1, 7, 9,-trien-l l, 13, 15-triyne, tetradeca-8, 10, 12,-trine-6-ene-3-one, and methyl 2-decen-4, 6, 8-triynate.
  • the small branch contains substances acting like oxytoxin. Furthermore, ridentin of sesquiterpene lactone is extracted.
  • Guava (psidium guajava L.) is a small tree native to America and belonging to the
  • guava Myrtaceae family and the Psidium genus. The leaves, the bark of a tree, and the fruit are used for health food and medicinal purposes. With a high propagation power, guava can be cultivated without agricultural chemicals. It is generally known that guava is effective in dysentery and diarrhea.
  • the most highly contained ingredient of guava is tannin, which is effective in reinforcing a gastrointestinal function, inhibiting aging, and treating cancer.
  • vitamins and minerals such as oils, gasoline, insulin, vitamin B complex, vitamin C, magnesium, and potassium are contained.
  • medicinal actions such as sterilization, anti-diarrhea, anti-inflammatory, stoppage of bleeding, inhibition of histamine release, decrease in blood sugar, anti-oxidation, and inhibition of vascular permeability are known (Ahn, D. G., the Korean pictorial book of medical herbs, Kyohak Publishing Company, 1999).
  • Asparagus (Asparagus officinalis L.) is a perennial herb and all of its root, stem, leaf, flower, seedcase and seed contain a kind of flavone.
  • the root and stem contain asparagine, steroidsaponin glycoside, coumarin, carotene, and oil.
  • steroidsaponin is also referred to as sarsasapogenin.
  • the leaf contains asparagine, carotene, glutathione, rutin (This is contained 100mg% in end parts of a new branch and 30mg% in the stem.), vitamin C (This is contained 25mg% in a new stem and 252.5mg% in a trunk.), carbohydrate (almost glucose), and peptidase.
  • the leaf contains rutin and four kinds of flavone compounds, which are hydrolyzed to quercetin, glucose, and rhamnose.
  • the ripe fruit contains saccharide, fat, capsanthin, and alkaloid.
  • the seed contains glucomannan in which mannose and glucose are 1: 1 in molecular weight ratio.
  • the herb contains asparagin, coniferin, saponin, and helidonin (Jeong, B. S., et al., the Korean medicinal stuff dictionary, YoungLim Book Center, ppl65-166, 1998).
  • the present invention provides a use of a composition including an extract of aloe vera, an extract of green tea leaves, an extract of wormwood, an extract of guava leaves, an extract of asparagus, vitamin C, and vitamin B complex.
  • the present invention further provides a pharmaceutical composition including an extract of aloe vera, an extract of green tea leaves, an extract of wormwood, an extract of guava leaves, an extract of asparagus, vitamin C, and vitamin B complex, and also including a pharmaceutically permissible carrier, excipient, or diluent.
  • the present invention still further provides a method for preventing or remedying liver injury by giving a medicine to a human or a mammal, the medicine including an extract of aloe vera, an extract of green tea leaves, an extract of wormwood, an extract of guava leaves, an extract of asparagus, vitamin C, and vitamin B complex, and also including a pharmaceutically permissible carrier or excipient.
  • an extract is dissolved in water, lower alcohol Cl to C4 such as ethanol, methanol, and butanol, or their mixture, and preferably in water.
  • vitamin B complex includes vitamin Bl (thiamin), vitamin B2
  • vitamin B3 riboflavin
  • vitamin B5 pantothenic acid
  • vitamin B6 pyridoxine
  • vitamin B 12 cobalmin
  • vitamin B7 biotin; vitamin H
  • vitamin B9 folic acid; vitamin M
  • the above composition has the following mixed rates of a 20-40 weight
  • % aloe vera extract a 10-30 weight % green tea leaves extract, a 5-20 weight % wormwood extract, a 5-15 weight % guava leaves extract, a 5-15 weight % asparagus extract, a 0.5-5 weight % vitamin C, and a 0.5-5 weight % vitamin B complex.
  • Extracts of the present invention may be obtained as follows.
  • aloe vera, green tea leaves, wormwood, guava leaves, and asparagus are respectively dried and then ground to powder.
  • Dried powder is dissolved in a solvent which is water or lower alcohol such as ethanol, methanol, and butanol.
  • the volume of such a solvent is about 1 to 20 times, preferably about 2 to 7 times, of the weight of dried powder.
  • a solvent may be a mixture of water and lower alcohol, which have a ratio of about 1 :0.1 or 1 : 10. Water is preferable as a solvent.
  • Extraction temperature and time are 20 to 100 0 C, preferably 60 to 8O 0 C, and about 0.5 hours to 2 days, preferably 1 hour to 1 day.
  • a water-hot extraction, an enfleurage extraction, a reflux condensing extraction, or an ultrasonic extraction is carried out once to five times, preferably three times.
  • An extract is then filtrated with a reduced pressure.
  • a filtrated extract is concentrated using a vacuum rotating concentrator with a reduced pressure at 20 to 100 0 C, preferably 20 to 7O 0 C.
  • the present invention provides a pharmaceutical composition that includes extracts of aloe vera, green tea leaves, wormwood, guava leaves, and asparagus, which are obtained by the above-described method.
  • This composition also includes vitamin C and vitamin B complex.
  • a pharmaceutical composition of the present invention may further include carrier, excipient, and diluent, which are normally used in the manufacture of pharmaceutical compositions.
  • a pharmaceutical medication of a composition according to the present invention may be given in the form of a pharmaceutically permissible salt, independently, or in combination with other pharmaceutical active compounds.
  • a pharmaceutical composition of the present invention may be formed into oral types such as powder, granule, pill, capsule, suspension, emulsion, syrup, and aerosol, external remedy types, suppository types, and injection types.
  • Carrier, excipient, and diluent included in a composition may be lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral.
  • filler, diluent, binder, humectant, disintegrator, or surfactant may be used to make a medicine.
  • a solid medicine for oral medication may be pill, powder, granule, or capsule, which may be made of the above composition and at least one excipient, e.g., starch, calcium carbonate, sucrose, lactose, and gelatin. Additionally, lubricant such as magnesium stearate or talc may be used.
  • a liquid medicine for oral medication may be suspension, solution, emulsion, or syrup, which may be mixed in wafer or liquid paraffin, and may include humectant, sweetener, aromatic, or preservative.
  • a medicine for non-oral medication may be a sterilized aqueous solution, a non-aqueous solvent, suspension, emulsion, freeze drying medicine, or suppository.
  • non-aqueous solvent and suspension vegetable oil such as propylene glycol, polyethylene glycol, and olive oil, or injectable ester such as ethylolate may be used.
  • Witepsol, macrogol, tween 61, cacao oil, laurin oil, or glycerogelatin may be used for suppository.
  • Preferable dosage of a composition of the present invention may be suitably selectable and depend on a condition and a weight of patient, a degree of disease, a form of medicine, and a path and a term of medication.
  • dosage of a composition of the invention may be 0.0001 to 100 mg/kg per day, preferably 0.001 to 100 mg/kg per day. Medication may be once a day or several times a day.
  • a composition of the present invention may be medicated through several paths to mammal such as rat, mouse, livestock, and human.
  • a medication may be conducted by means of oral administration, rectal administration, intravenous injection, intramuscular injection, subcutaneous injection, or intracerebroventricular injection.
  • composition of the present invention may be safely used even in a long-term use for prevention.
  • the present invention provides a functional food for protecting liver cells and preventing liver injury, the functional food including an extract of aloe vera, an extract of green tea leaves, an extract of wormwood, an extract of guava leaves, an extract of asparagus, vitamin C, and vitamin B complex, and also including additive with permissible in sitology.
  • a functional food of the present invention includes the aforesaid composition in the form of powder or extract.
  • a composition of the present invention may be variously used in medicine, food, beverage, etc. for an improvement in the liver.
  • a composition of the invention may be added to a great variety of food such as beverage, chewing gum, tea, vitamin compound, and additive food, in the form of pill, powder, granule, infusion, capsule, or beverage.
  • a composition may occupy 0.01 to 15 weight % of food or beverage.
  • a composition may be added with 0.02 to 5g, preferably 0.3 to Ig, in 100ml.
  • a composition in beverage may contain any other conventional ingredients such as flavor or natural saccharide.
  • natural saccharide there are monosaccharide such as glucose and fructose, disaccharide such as maltose and sucrose, polysaccharide such as dextrin, cyclodextrin, xylitol, sorbitol, and erythritol.
  • flavor there are natural flavor such as thaumatin and stevia extract (e.g., rebaudioside A and glycyrrhizin), and synthetic flavor such as saccharin and aspartame.
  • a natural saccharide may be generally about 1 to 2Og, preferably about 5 to 12g, in a composition of 100ml.
  • a composition of the present invention may contain nutrient, vitamin, mineral (electrolyte), natural or synthetic flavor, stain (cheese or chocolate), pectic acid and salt, alginic acid and salt, organic acid, protective colloid, pH conditioner, stabilizer, preservative, glycerin, alcohol, and carbonation reagent.
  • a composition of the invention may contain flesh of fruit used for juice or beverage. These additives may be added independently or in combination with 0 to 20 weight parts per 100 weight of a composition according to the present invention.
  • a composition of the present invention is effective in liver protection and safe to human, so that this composition may be available for a pharmaceutical composition and a health functional food for protection of liver cells and prevention or remedy of liver injury.
  • FIG. 1 is a diagram showing an experimental result of liver cell toxicity in various densities of a composition according to the present invention.
  • FIG. 2 is a diagram showing an effect of liver cell protection against t-BHP-induced toxicity of a composition according to the present invention.
  • FIG. 3 is a diagram showing a measurement data of GOT and LDH in a culture medium using a HepG2 cell in which toxicity is induced by t-BHP to verify an effect of liver cell protection of a composition according to the present invention.
  • Aloe vera, green tea leaves, wormwood, guava leaves, and asparagus were acquired in a store and a market. Aloe vera, green tea leaves, wormwood, guava leaves, and asparagus, each of which is lkg, were dried and ground. Resultant powders each of which is 300 to 600g were put in a bottle, and distilled water of 2 liters was put in too. Then water-hot extraction was carried out three times at regular intervals (12h, 6h, 3h) with a temperature of 7O 0 C. An extract was filtrated using a filter paper (Whatman, U.S.) with a reduced pressure.
  • a filter paper Whatman, U.S.
  • Distilled water was removed from a filtrated extract at a temperature of 4O 0 C by using a vacuum rotating concentrator.
  • aloe vera, green tea leaves, wormwood, guava leaves, and asparagus which are 15g, 5 Ig, 25g, 24g, and 1Og, respectively, were obtained as water-soluble extracts.
  • aloe vera, green tea leaves, wormwood, guava leaves, and asparagus were obtained to 75g, 255g, 125g, 12Og, and 50g, respectively.
  • Respective extracts were prepared in the form of powder by using a spray dryer or a freezing dryer, and kept with absorption of moisture restrained at a temperature of 4 0 C.
  • a HepG2 cell which is a human hepatocellular carcinoma cell line, was received from Korean Cell Line Bank and subcultured.
  • a culture medium was MEM- ⁇ containing penicillin G of 100 IU/ml and streptomycin of 100 mg/ml, mixed with FBS which is 10% of a total amount, and regulated to pH 7.4.
  • a HepG2 cell was cultivated in an incubator under 37 0 C, 5% CO for 2-3 days. Cells were separated through trypsin-EDTA treatment and regulated to 1X10 cell/ml per well. Then cells of 100 ⁇ l were put in each well and preliminarily cultivated in a CO incubator under 37°C, 5% CO for 24 hours. After a culture medium was removed, cells were treated with compositions having various densities and cultivated in a CO incubator under 37°C, 5% CO for 48 hours. Then a survival rate of cells was measured by means of MTT assay.
  • MTT assay was conducted as follows, using a technique proposed by Sladowski D. et al., An improved MTT assay. J. Immun. Methods, 157, pp203 ⁇ 207, 1993. An MTT solution of 5 ⁇ g/ml with PBS was applied to 96 well plates in which HepG2 cells were cultivated. These well plates were left in a CO incubator under 37 0 C, 5% CO for 2
  • a survival rate of cells to which compositions having the maximum density of 5,500 ⁇ g/ml were added was 85.5% in comparison with a survival rate of cells in a control group with no treatment was defined as 100%.
  • a survival rate of cells in an experimental group treated with a density not exceeding 2,750 ⁇ g/ml was 100-150%. This means that no necrosis of cells was caused by a composition. It was therefore verified that a pretreatment with a composition having a density not exceeding 2,750 ⁇ g/ml did not induce a significant toxicity in cultivated liver cells (See FIG. 1).
  • BHP final density ImM
  • MTT assay was conducted as follows, using a technique proposed by Sladowski D. et a ⁇ ., An improved MTT assay. J. Immun. Methods, 157, pp203 ⁇ 207, 1993.
  • An MTT solution of 5 ⁇ g/ml with PBS was applied to 96 well plates in which HepG2 cells were cultivated. These well plates were left in a CO incubator under 37°C, 5% CO for 2 r 2 2 hours. After supernatant was removed, DMSO and EtOH (1:1 v/v) of 100 ⁇ l were put in each well and shaken for 20 minutes.
  • MTT pigment (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) forms blue formazan by mitochondrial dehydrogenase.
  • HepG2 cells were treated with compositions of several densities, and t-BHP was added up to ImM. Then cells were cultivated in a CO incubator under 37 0 C, 5% CO
  • a survival rate of cells in an experimental group treated with t-BHP only was remarkably reduced to 32.04% in comparison with a survival rate of cells in a control group with no treatment was defined as 100%.
  • a survival rate of cells in another experimental group pretreated with compositions of 2,750, 1,375, 687.5, 343.8, and 171.9 ⁇ g/ml per well and then treated with t-BHP was 149.62, 150.57, 97.34, 52.79, and 50.81%, respectively.
  • a survival rate of cells was remarkably increased in a jointly treated group of 2,750, 1,375, and 687.5 ⁇ g/ml than in a singly treated group of t-BHP (See FIG. 2).
  • This experiment was carried out in order to measure the activity of GOT and LDH in a cell culture medium of a BS-I composition. Liver cells were distributed with 3ml in 6 wells at 5X10 cell/ml and preliminarily cultivated for 24 hours. Cells were treated with compositions by density and cultivated in a CO incubator under 37 0 C, 5% CO for 48 hours. Then t-BHP (final density ImM) was added, and cells were cultivated again in a CO incubator under 37 0 C, 5% CO for 5 hours. After each cell culture
  • LDH lactate dehydrogenase
  • GOT glutamic oxaloacetic transaminase
  • This experiment used a Sprague-Dawley rat of Orient Bio Inc. (Korea), tetrachloride of Sigma (USA), a corn oil of CJ (Korea), and a kit of Asan Phar- maceutical (Korea).
  • This kit was used to measure the activity of enzymes such as GPT (glutamate pyruvate transaminase), GOT (glutamate oxaloacetate transaminase), and LDH (lactate dehydrogenase).
  • a male rat of Sprague-Dawley which was 260-28Og and 7 weeks old, was adapted to an environment for 1 week. This male rat freely took feed (Samtako, Korea) and water in an animal facility in which a brightness cycle was automatically regulated every 12 hours (07:00 s 19:00) at a temperature of 22-25°C.
  • composition of BS-I was orally administered once a day at the fixed time with 1.8g per weight kilogram for 10 days.
  • Experimental groups were classified into three groups, namely, a control group (normal), a group with tetrachloride (CCl ) only, and a group with tetrachloride (CCl ) after treated with a composition (BS-I).
  • tetrachloride was dissolved in a corn oil at a ratio of 1:1 (v/v) and administered by an intraperitoneal injection with 2.0 ml/kg/day. In a control group, a corn oil only was administered.
  • a mixing ratio of vitamin and mineral may be varied. According to a conventional method for manufacturing a health functional food, the above ingredients are mixed and made in the form of granule.
  • a composition of the present invention is effective in liver protection and safe to human, so that this composition may be available for a pharmaceutical composition and a health functional food for protection of liver cells and prevention or remedy of liver injury.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Une composition de la présente invention est efficace dans la protection du foie et sans dangers pour les humains, si bien que cette composition peut être mise à disposition pour une composition pharmaceutique, et un aliment fonctionnel sanitaire pour la protection des cellules hépatiques et la prévention ou le traitement de lésion hépatique.
PCT/KR2006/003817 2006-07-21 2006-09-26 Compositions comprenant les extraits de matières premières pour améliorer la fonction hépatique WO2008010620A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2006-0068577 2006-07-21
KR20060068577 2006-07-21

Publications (1)

Publication Number Publication Date
WO2008010620A1 true WO2008010620A1 (fr) 2008-01-24

Family

ID=38956937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/003817 WO2008010620A1 (fr) 2006-07-21 2006-09-26 Compositions comprenant les extraits de matières premières pour améliorer la fonction hépatique

Country Status (1)

Country Link
WO (1) WO2008010620A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585323A (zh) * 2012-08-14 2014-02-19 覃德光 治疗乙肝病毒大小三阳的中药制剂
JP2017508801A (ja) * 2014-03-10 2017-03-30 フィトテック エクストラクツ ピーヴイティー リミテッド 標準化された植物化学物質を有する水溶性バンジロウ葉抽出物
EP3127547A4 (fr) * 2014-04-04 2018-01-03 Amorepacific Corporation Composition comprenant un extrait de feuilles de génépi blanc

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62103017A (ja) * 1985-10-28 1987-05-13 Res Inst For Prod Dev 抗肝炎剤
JPH04300836A (ja) * 1991-03-29 1992-10-23 Nikko Kyodo Co Ltd 肝機能障害予防剤及び肝機能障害予防作用を有する機能性食品
JP2003137802A (ja) * 2001-10-26 2003-05-14 Kyowa Hakko Kogyo Co Ltd 肝機能保護剤または改善剤
WO2004041176A2 (fr) * 2002-10-31 2004-05-21 Kemin Foods L.C. Utilisation d'endoperoxydes pour le traitement d'infections causees par un flaviviridae, telles que l'hepatite c, la diarrhee virale bovine et le virus de la peste porcine classique
KR20050022250A (ko) * 2003-08-30 2005-03-07 삼아약품 주식회사 녹차카테킨을 유효성분으로 포함하는 간 기능 개선제
KR100496524B1 (ko) * 2002-12-13 2005-06-22 주식회사 오리온 숙취해소용 조성물
KR20060016552A (ko) * 2004-08-18 2006-02-22 고려대학교 산학협력단 알코올 유도 ｃｙｐ２ｅ１이 생성한 활성산소종으로부터간세포 보호활성을 갖는 카테킨류 화합물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62103017A (ja) * 1985-10-28 1987-05-13 Res Inst For Prod Dev 抗肝炎剤
JPH04300836A (ja) * 1991-03-29 1992-10-23 Nikko Kyodo Co Ltd 肝機能障害予防剤及び肝機能障害予防作用を有する機能性食品
JP2003137802A (ja) * 2001-10-26 2003-05-14 Kyowa Hakko Kogyo Co Ltd 肝機能保護剤または改善剤
WO2004041176A2 (fr) * 2002-10-31 2004-05-21 Kemin Foods L.C. Utilisation d'endoperoxydes pour le traitement d'infections causees par un flaviviridae, telles que l'hepatite c, la diarrhee virale bovine et le virus de la peste porcine classique
KR100496524B1 (ko) * 2002-12-13 2005-06-22 주식회사 오리온 숙취해소용 조성물
KR20050022250A (ko) * 2003-08-30 2005-03-07 삼아약품 주식회사 녹차카테킨을 유효성분으로 포함하는 간 기능 개선제
KR20060016552A (ko) * 2004-08-18 2006-02-22 고려대학교 산학협력단 알코올 유도 ｃｙｐ２ｅ１이 생성한 활성산소종으로부터간세포 보호활성을 갖는 카테킨류 화합물

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AUGUSTYNIAK A. ET AL.: "Preventive action of green tea from changes in the liver antioxidant abilities of different aged rats intoxicated with ethanol", NUTRITION, vol. 21, no. 9, 2005, pages 925 - 932 *
CHOI B.B. ET AL.: "Studies on the volatile flavor components and biochemical characterizations of Artemisia princeps A and A. argyi", KOREAN J. FOOD & NUTR., vol. 18, no. 4, 2005, pages 334 - 340, XP053009532 *
FAN Y.J. ET AL.: "Protective effect of extracts from Aloe vera L. var. chinensis (Haw.) Berg. on experimental hepatic lesions and a primary clinical study on the injection of in patients with hepatitis", ZHONGGUO ZHONG YAO ZA ZHI, vol. 14, no. 12, 1989, pages 746 - 748 *
HE P. ET AL.: "Green tea suppresses lipopolysaccharide-induced liver injury in D-galactosamine-sensitized rats", J. NUTR., vol. 131, no. 5, 2001, pages 1560 - 1567 *
JIAO H.L. ET AL.: "Protective effects of green tea polyphenols on human HepG2 cells against oxidative damage of fenofibrate", FREE RADIC. BIOL. MED., vol. 35, no. 9, 2003, pages 1121 - 1128 *
KISO Y. ET AL.: "Antihepatotoxic principles of Artemisia capillaris buds1", PLANTA MED., vol. 50, no. 1, 1984, pages 81 - 85, XP008109207, DOI: doi:10.1055/s-2007-969627 *
MIYAGAWA C. ET AL.: "Protective effect of green tea extract and tea polyphenols against the cytotoxicity of 1,4-naphthoquinone in isolated rat hepatocytes", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 61, no. 11, 1997, pages 1901 - 1905 *
NORIKURA T. ET AL.: "Protective effect of aloe extract against the cytotoxicity of 1,4-naphthoquinone in isolated rat hepatocytes involves modulations in cellular thiol leves", PHARMACOL. TOXICOL., vol. 90, no. 5, 2002, pages 278 - 284 *
PARK E.J. ET AL.: "The ethanol-soluble part of a host-water extract from Artemisia iwayomogi inhibits liver fibrosis induced by carbon tetrachloride in rats", J. PHARM. PHARMACOL., vol. 52, no. 7, 2000, pages 875 - 881 *
ROY C.K. ET AL.: "Hepatoprotective activity of Psidium guajava Linn. leaf extract", INDIAN J. EXP. BIOL., vol. 44, no. 4, April 2006 (2006-04-01), pages 305 - 311 *
SAI K. ET AL.: "Protective effects of green tea on hepatoxicity, oxidative DNA damage and cell proliferation in the rat liver induced by repeated oral administration of 2-nitropropane", FOOD CHEM. TOXICOL., vol. 36, no. 12, 1998, pages 1043 - 1051 *
XIAO J. ET AL.: "Green tea extracts protected against carbon tetrachloride-induced chronic liver damage and cirrhosis", ZHONGHUA YU FANG YI XUE ZA ZHI, vol. 36, no. 4, 2002, pages 243 - 246 *
YE M.R. ET AL.: "Pharmacological study on Asparagus officinalis Linn", ZHONGGUO ZHONG YAO ZA ZHI, vol. 19, no. 4, 1994, pages 240 - 242 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585323A (zh) * 2012-08-14 2014-02-19 覃德光 治疗乙肝病毒大小三阳的中药制剂
JP2017508801A (ja) * 2014-03-10 2017-03-30 フィトテック エクストラクツ ピーヴイティー リミテッド 標準化された植物化学物質を有する水溶性バンジロウ葉抽出物
EP3127547A4 (fr) * 2014-04-04 2018-01-03 Amorepacific Corporation Composition comprenant un extrait de feuilles de génépi blanc

Similar Documents

Publication Publication Date Title
Muhammad et al. A review on promising phytochemical, nutritional and glycemic control studies on Moringa oleifera Lam. in tropical and sub-tropical regions
Osuna-Martínez et al. Cactus (Opuntia ficus-indica): A Review on its Antioxidants Properties and Potential Pharmacological Use in Chronic Diseases. Nat Prod Chem Res 2: 153
Kumari et al. Tannins: An antinutrient with positive effect to manage diabetes
Khristi et al. Therapeutic potential of Hibiscus rosa sinensis: A review
Parthasarathy et al. Antidiabetic activity of Thespesia Populnea bark and leaf extract against streptozotocin induced diabetic rats
KR100834850B1 (ko) 항알레르기성 비염, 항아토피성 피부염 또는 항만성천식 효과를 지니는 복합생약 조성물
Fattaheian-Dehkordi et al. A review on antidiabetic activity of Centaurea spp.: A new approach for developing herbal remedies
EP2091545B1 (fr) Composition comprenant un extrait d'herbes combinées utilisée pour prévenir et traiter des maladies hépatiques
KR101077523B1 (ko) 황칠나무 및 비파엽으로 구성된 군으로부터 선택된 하나 이상의 생약 추출물을 유효성분으로 함유하는 퇴행성 뇌질환 치료 및 예방용 조성물
Rahman et al. Bioactive compounds and diabetes mellitus: prospects and future challenges
WO2008010620A1 (fr) Compositions comprenant les extraits de matières premières pour améliorer la fonction hépatique
KR101470603B1 (ko) 흡연시 발생하는 유해성분 제거용 생약추출물의 제조방법
CN102614228B (zh) 松针脂溶性提取物在制备治疗肿瘤药物中的应用
Rtibi et al. In vitro α-amylase/α-glucosidase inhibitory activities and in vivo improving glucose tolerance and hypoglycemic effect of Ceratonia siliqua leaves aqueous extract
KR101023487B1 (ko) 오미자, 황금 및 해동피의 혼합 생약재 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물
WO2008069604A1 (fr) Composition comprenant l'extrait végétal mixte de aralia cordata thunb. et cimicifuga heracleifolia kom. pour la prévention et le traitement de l'inflammation et de la douleur
Pandeya et al. Antidiabetics review on natural products
KR101636608B1 (ko) 산수유 추출물을 포함하는 항산화용 조성물
Łabuda et al. Secondary metabolites of Phaseoli pericarpium
Maji Role of Neem leaves in Diabetes and Obesity
KR20080101848A (ko) 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품
Satla Comparative In vitro antidiabetic and antioxidant activity of Pulicaria wightinia, Curcuma inodora, Derris scandens leaf extracts
KR100538983B1 (ko) 생약추출물이 함유된 간기능 개선용 약학 조성물
Rabeque A review on phytochemical, antioxidant, and Hypoglycemic activity of traditionally important Syzygium spp
KR101483121B1 (ko) 고지혈증의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06798900

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06798900

Country of ref document: EP

Kind code of ref document: A1